NCI’s Global Cancer Medicine Humanitarian Award awarded to Pat Garcia-Gonzalez

Boston, Massachusetts; USA

The Max Foundation is proud to announce CEO, Pat Garcia-Gonzalez as the recipient of the National Cancer Institute Global Cancer Medicine Humanitarian Award at the U.S. National Cancer Institute 3rd Annual Symposium on Global Cancer Research held in Boston on 25 March 2015.

In the award letter from the National Cancer Institute (NCI), Dr. Edward L. Trimble, MD, MPH, Director of the NCI’s Center for Global Health writes about Pat: “Our global cancer community has been inspired by your outstanding contributions to advancing cancer care equity through The Max Foundation, and as recognition of that work, we would like to honor you.”

Dr. Trimble continues, “Not only have your efforts saved numerous lives, but, to paraphrase Donald Berwick, your contributions go beyond health metrics and health indicators— your contributions will allow mothers and fathers to attend graduations and weddings they would have missed, and grandchildren to know grandparents they might never have known, “and holidays will be taken, and work completed, and books read, and symphonies heard, and gardens tended that, without your work, would never have been.’”

In response to the award, Pat has said, “I am humbled, excited and honored by the recognition given to me thanks to NCI’s Center for Global Health. I see this moment as an opportunity to tell the world about the great collaborations that have made my work possible, as well as a chance to reinforce our collective responsibility around creating solutions to increase global access to treatment, care and support for people living with cancer around the world.”

This is the first Global Cancer Medicine Humanitarian Award to be given at the NCI’s Symposium.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation welcomes John Menapace as CFO/VP of Administration

    The Max Foundation welcomes John Menapace as CFO/VP of Administration

    We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration. John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies.  His prior roles include positions….

  • The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023

    The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023

    The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG First patients to receive treatment in Bahamas, Benin, Bhutan, Haiti, Jamaica, Mozambique,….

  • UICC announces a new global coalition to increase access to and the  use of essential cancer medicines in low- and lower middle-income  countries

    UICC announces a new global coalition to increase access to and the use of essential cancer medicines in low- and lower middle-income countries

    The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries (LLMICs) and to help countries develop the capacity for their proper use. It is estimated that less than….